In today’s recent session, 66.22 million shares of the Evoke Pharma Inc (NASDAQ:EVOK) have been traded, and its beta is -0.08. Most recently the company’s share price was $6.88, and it changed around $4.22 or 158.65% from the last close, which brings the market valuation of the company to $10.27M. EVOK at last check was trading at a discount to its 52-week high of $12.32, offering almost -79.07% off that amount. The share price’s 52-week low was $1.94, which indicates that the recent value has risen by an impressive 71.8% since then. We note from Evoke Pharma Inc’s average daily trading volume that its 10-day average is 13330.0 shares, with the 3-month average coming to 15.70K.
Evoke Pharma Inc stock received a consensus recommendation rating of Overweight, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 1 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 0 recommended EVOK as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight. Evoke Pharma Inc is expected to report earnings per share of -0.3 for the current quarter.
Evoke Pharma Inc (NASDAQ:EVOK) trade information
Instantly EVOK has been showing a green trend so far today with a performance of 158.65% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 9.79 on recent trading dayincreased the stock’s daily price by 29.72%. The company’s shares are currently up 6.17% year-to-date, but still up 158.65% over the last five days. On the other hand, Evoke Pharma Inc (NASDAQ:EVOK) is 133.22% up in the 30-day period. We can see from the shorts that 17702.0 shares have been sold at a short interest cover period of 1.01 day(s).
The consensus price target as assigned by Wall Street analysts is $18, which translates to bulls needing to increase their stock price by 61.78% from its current value. Analyst projections state that EVOK is forecast to be at a low of $18 and a high of $18.
Evoke Pharma Inc (EVOK) estimates and forecasts
The year-over-year growth rate is expected to be 54.73%, up from the previous year.
Consensus estimates provided by 1 financial analysts predict the company will bring in an average of 3.8M in revenue for the current quarter. 1 analysts expect Evoke Pharma Inc to make 4.33M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 2.55M and 2.65M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 48.78%. Forecasts for the next quarter put sales growth at 62.99%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 42.83%.
EVOK Dividends
Evoke Pharma Inc’s next quarterly earnings report is expected to be released on 2025-May-13.
Evoke Pharma Inc (NASDAQ:EVOK)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.34% of Evoke Pharma Inc shares, and 16.23% of them are in the hands of institutional investors. The stock currently has a share float of 16.45%.
Fidelity Concord Street Trust-Fidelity Extended Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund were the top two Mutual Funds as of May 31, 2025 . The former held 6.41 shares worth $44899.0, making up 0.43% of all outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund held roughly 2.49 shares worth around $17433.0, which represents about 0.17% of the total shares outstanding.
